Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11626642 | 0.84 | NPC1 (0.72) | NPC1MEN1KMT2ARAB9AEPHX2 | |
| SCHEMBL8395990 | 0.83 | NPC1 (0.73) | NPC1MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL8393668 | 0.83 | NPC1 (0.73) | NPC1MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL8396806 | 0.81 | NPC1 (0.70) | NPC1MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL335312 | 0.80 | AIMP2 (0.49) | NPC1SIGMAR1EGFRERBB2 | |
| SCHEMBL23302363 | 0.78 | NPC1 (0.64) | NPC1MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL8395513 | 0.78 | NPC1 (0.66) | NPC1MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL29836780 | 0.78 | MEN1 (1.00) | NPC1MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL2575801 | 0.77 | NPC1 (0.74) | NPC1MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL11630837 | 0.77 | NPC1 (0.65) | NPC1RAB9AALDH1A1EPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782996-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-02-24 | — | — | EP | disclosed |
| EP-3307739-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-20180179187-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179187-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | NPC1 505/4885MEN1 4838/4885KMT2A 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.